Empty Picornaviral Capsid Production via Mutated 3C Protease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing empty Foot and Mouth Disease Virus (FMDV) capsids face challenges with low yield and stability, primarily due to high levels of 3C protease toxicity in host cells, which hinder the production of immunogenic and commercially viable vaccine products.
Innovation Solution
A construct comprising a nucleotide sequence encoding a P1 capsid precursor protein, a mutated 3C protease with reduced activity, and a retrovirus frameshift site to control protease expression, ensuring sufficient cleavage without inducing toxicity, is used to produce empty FMDV capsids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high levels of 3C protease are expressed to cleave the capsid precursor protein, then capsid processing efficiency is improved, but host cell toxicity increases
Solution Approach 1:
The patent applies parameter changes by mutating the 3C protease at position 142 (C142) to reduce its enzymatic activity. This modified protease maintains sufficient cleavage capability to process the capsid precursor protein while operating at lower activity levels that prevent host cell toxicity, thereby resolving the contradiction between processing efficiency and cellular health
Solution Approach 2:
The retrovirus frameshift site serves as an intermediary control element that regulates 3C protease expression. By introducing this frameshift mechanism, the system achieves controlled, reduced-level expression of the protease, enabling it to perform its cleavage function without reaching toxic concentrations in the host cell
2Reliability
If conventional whole virus vaccines are used, then immunogenicity is improved, but risk of virus release and improper inactivation increases
Solution Approach 1:
The patent extracts only the structural components (capsid proteins) from the complete virus particle, producing empty capsids that lack the RNA genome and replication machinery. These empty capsids retain the immunogenic external structure of the wild-type virus while being non-replicative and non-infectious, thereby eliminating the risk of virus release while maintaining immunogenicity
Solution Approach 2:
The patent creates a copy of the virus's external structure (capsid) without the internal genetic material. The empty capsids are antigenic copies that mimic the wild-type virus surface, providing immunogenicity without the harmful properties of replicating virus particles
3Reliability
If empty capsids are produced using existing methods, then safety is improved, but yield and stability deteriorate
Solution Approach 1:
The patent applies parameter changes through the C142 mutation of the 3C protease, which modifies the enzymatic activity parameter to an optimal range. This adjusted protease activity enables efficient capsid production with improved yield and stability while maintaining the safety advantages of empty capsid systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in high-yield, stable production of FMDV empty capsids, reducing toxicity and enhancing immunogenicity, making them suitable for vaccine development without the need for high-security containment facilities.
Implementation Method 1
a retrovirus frameshift site to control protease expression
Implementation Method 2
a mutated 3C protease with reduced activity... capable of cleaving the picornavirus capsid precursor protein
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention provides a construct which, when expressed in a host cell, is capable of producing empty virus capsids, the construct comprising: (i) a nucleotide sequence encoding a capsid precursor protein; (ii) a nucleotide sequence encoding a protease capable of cleaving the capsid precursor protein; and (iii) a control element which controls the expression of the protease such that, when the construct is present in the host cell, the control element causes the protease to be expressed at a level sufficient to cleave the capsid precursor protein, but not sufficient to induce significant toxicity in the host cell. The invention also provides a vector and a host cell comprising such a construct and their use to generate empty virus capsids.